En Carta secures $6.18m to expand molecular testing solutions

French deep-tech company En Carta Diagnostics has announced the first closing of €5m ($6.18m) in financing to scale its at-home molecular diagnostic solutions.

The funding comprises €3m in equity investment led by Blue Forest Ventures, with participation from Ring Capital, existing investors 50 Partners Health, CentraleSupélec Venture, and business angels. It also includes €2m in non-dilutive funding from Bpifrance and other partners.

The company plans to allocate the proceeds to pursue regulatory certification for its molecular testing products in Europe and the US, and scale up manufacturing through a fabless model via a partnership with Circum Medical for hardware production.

It also aims to launch the platform commercially, beginning with early Lyme disease detection and later extending to areas such as sexually transmitted infection (STI) screening.

En Carta Diagnostics is conducting two clinical trials of its flagship Lyme disease detection product, with studies underway in Boston, US, and Bialystok, Poland.

The company received an FDA breakthrough device designation for this solution in January 2026, which provides access to an accelerated regulatory pathway in the US market.

Later, En Carta Diagnostics entered a co-development and commercialisation agreement with AAZ, a company established in self-tests and rapid diagnostics.

Valued at €13m, the partnership aims to develop and supply rapid molecular tests for chlamydia and gonorrhoea in Europe, targeting several million units over five years.

En Carta Diagnostics co-founder and CEO Guillaume Horreard said: "From FDA breakthrough designation to a €13m commercial partnership, and now €5m in financing, En Carta is delivering.

"Our next milestone is getting our two products, a rapid molecular diagnostic for Borrelia, the bacteria responsible for Lyme disease, and an STI screening test, into the hands of patients and clinicians across Europe and the US.

"This first closing brings us closer to our mission of transforming access to testing. By enabling patients to perform reliable molecular tests wherever they are, we can support earlier diagnosis, improve patient outcomes, and help relieve pressure on healthcare systems."

"En Carta secures $6.18m to expand molecular testing solutions" was originally created and published by Medical Device Network, a GlobalData owned brand.